Announced details
DDAIF has been adopted by multiple major pharmaceutical companies (cumulative number: Not disclosed)
In January 2026, the companies entered into a proof-of-concept (PoC) agreement covering the exploration of novel target molecules and indications for next-generation nucleic acid aptamers. The companies will now jointly undertake a second research and development initiative.
Based in Meguro-ku, Tokyo, and led by President and Representative Director Koseki Chizuko (古関 千寿子), this University of Tokyo startup develops pharmaceuticals and diagnostic technologies using next-generation nucleic acid aptamers based on artificial base-pair technology.
FRONTEO has obtained 21 patent rights in total in Japan, Europe, the United States and South Korea for technologies related to DDAIF (individual patent numbers and expiration dates: Not disclosed)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, Xenoligo® (next-generation nucleic acid aptamer platform), Next-generation nucleic acid aptamers |
| Counterparty | TagCyx Biotechnologies Inc. |
| Counterparty overview | Based in Meguro-ku, Tokyo, and led by President and Representative Director Koseki Chizuko (古関 千寿子), this University of Tokyo startup develops pharmaceuticals and diagnostic technologies using next-generation nucleic acid aptamers based on artificial base-pair technology. |
| Relationship with the Company | In January 2026, the companies entered into a proof-of-concept (PoC) agreement covering the exploration of novel target molecules and indications for next-generation nucleic acid aptamers. The companies will now jointly undertake a second research and development initiative. |
| Contract Date | January 2026 (PoC agreement; the body of the disclosure does not specify the exact date, while the related release cited in the footnote is dated 22 January 2026) |
| Launch date | 10 November 2026 (second initiative launched; actual date) |
| Applicable area | Drug Discovery, Pharmaceuticals, Diagnostic technology, Apheresis (blood purification therapy) |
| Registration number and expiry date | FRONTEO has obtained 21 patent rights in total in Japan, Europe, the United States and South Korea for technologies related to DDAIF (individual patent numbers and expiration dates: Not disclosed) |
| Usage history | DDAIF has been adopted by multiple major pharmaceutical companies (cumulative number: Not disclosed) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The initial AI analysis project identified multiple candidate diseases and targets, hypotheses regarding mechanisms of action, and candidates that could lead to applications in apheresis.